Recursion Pharmaceuticals Inc. stock reached a 52-week low, closing at $2.98. The biotechnology company, with a market capitalization of $1.58 billion, now trades 58% below its 52-week high of $7.18.
Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...
The prevailing assumption in AI development has been straightforward: larger models trained on more data produce better results. Nvidia's latest release directly challenges that size assumption — and ...
Erika Rasure is globally-recognized as a leading consumer economics subject matter expert, researcher, and educator. She is a financial therapist and transformational coach, with a special interest in ...
James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...
I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...